Lanean...
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disruptin...
Gorde:
| Argitaratua izan da: | Leuk Lymphoma |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6237652/ https://ncbi.nlm.nih.gov/pubmed/29764250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1457147 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|